These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 22997967

  • 1. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W, Sang W, Zheng S, Ma Y, Liu X, Zhang W.
    Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM, Ibrahim TR.
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [Abstract] [Full Text] [Related]

  • 3. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
    Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW.
    Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
    Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, Zhu X.
    J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
    [Abstract] [Full Text] [Related]

  • 5. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
    Mataraci EA, Ozgüven BY, Kabukçuoglu F.
    Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
    [Abstract] [Full Text] [Related]

  • 6. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, Hamdi MM, Abdullah MS.
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [Abstract] [Full Text] [Related]

  • 7. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD, Wang LJ, Yao HT, Li J, Ding W, Yan LP.
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [Abstract] [Full Text] [Related]

  • 8. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
    de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS.
    Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
    [Abstract] [Full Text] [Related]

  • 9. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W, Lu X, Zheng S, Ma Y, Liu X, Zhang W.
    Clin Lab; 2012 Oct; 58(5-6):419-26. PubMed ID: 22783570
    [Abstract] [Full Text] [Related]

  • 10. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
    Tong J, Wang Y, Da JP.
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
    [Abstract] [Full Text] [Related]

  • 11. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
    Torregrossa L, Faviana P, Camacci T, Materazzi G, Berti P, Minuto M, Elisei R, Vitti P, Miccoli P, Basolo F.
    Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
    [Abstract] [Full Text] [Related]

  • 12. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
    Aron M, Kapila K, Verma K.
    Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
    Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G.
    Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
    [Abstract] [Full Text] [Related]

  • 14. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
    Han RL, Wang J, Zhang FJ, Zhao N, Gao BL.
    Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
    [Abstract] [Full Text] [Related]

  • 15. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
    Tang QS, Teng XD, Ding W, Zhou J, Yao HT, Ying LX, Xu LM.
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
    [Abstract] [Full Text] [Related]

  • 16. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB, Şenol S, Şimşek BÇ, Sağıroğlu J, Aydın A.
    Int J Clin Exp Pathol; 2015 Nov; 8(4):3670-80. PubMed ID: 26097548
    [Abstract] [Full Text] [Related]

  • 17. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.
    Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO.
    Endocr Pathol; 2010 Jun; 21(2):80-9. PubMed ID: 20198455
    [Abstract] [Full Text] [Related]

  • 18. CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma.
    Chung SY, Park ES, Park SY, Song JY, Ryu HS.
    Head Neck; 2014 Jul; 36(7):1005-12. PubMed ID: 23784811
    [Abstract] [Full Text] [Related]

  • 19. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
    Nga ME, Lim GS, Soh CH, Kumarasinghe MP.
    Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
    Nechifor-Boilă A, Cătană R, Loghin A, Radu TG, Borda A.
    Rom J Morphol Embryol; 2014 Aug; 55(1):49-56. PubMed ID: 24715165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.